Amgen (AMGN) Total Debt (2009 - 2026)
Amgen (AMGN) posted quarterly Total Debt of $57.3 billion for Q1 2026, little changed year-over-year from $57.4 billion in Q1 2025, and up 4.98% quarter-over-quarter from $54.6 billion in Q4 2025.
Amgen (AMGN) Total Debt (2009 - 2026) Analysis & Trends
Amgen's Total Debt history runs 18 years deep, the most recent figure standing at $57.3 billion for Q1 2026.
- In Q1 2026, Total Debt changed 0.1% year-over-year to $57.3 billion; the TTM figure through Mar 2026 stood at $57.3 billion (changed 0.1% YoY), while the FY2025 annual figure was $54.6 billion, down 9.14% from the prior year.
- Total Debt for Q1 2026 stood at $57.3 billion, up from $54.6 billion in the prior quarter.
- The five-year high for Total Debt was $68.1 billion in Q2 2024, with the low at $37.3 billion in Q2 2022.
- The 5-year median for Total Debt is $58.6 billion (2025), against an average of $55.8 billion.
- The sharpest annual moves came in 2023 and 2025: Total Debt surged 65.91% in 2023, then declined 15.57% in 2025.
- Amgen's Total Debt stood at $38.9 billion in 2022, then soared by 65.91% to $64.6 billion in 2023, then decreased by 6.99% to $60.1 billion in 2024, then slipped by 9.14% to $54.6 billion in 2025, then rose by 4.98% to $57.3 billion in 2026.
- Business Quant data shows AMGN's Total Debt at $57.3 billion in Q1 2026, $54.6 billion in Q4 2025, and $56.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.75 Bn |
| Mar 31, 2026 | 57.32 Bn |
| Dec 31, 2025 | 54.60 Bn |
| Sep 30, 2025 | 56.74 Bn |
| Jun 30, 2025 | 58.65 Bn |
| Mar 31, 2025 | 57.38 Bn |
| Dec 31, 2024 | 60.10 Bn |
| Sep 30, 2024 | 63.94 Bn |
| Jun 30, 2024 | 68.13 Bn |
| Mar 31, 2024 | 67.96 Bn |
| Dec 31, 2023 | 64.61 Bn |
| Sep 30, 2023 | 61.93 Bn |
| Jun 30, 2023 | 61.54 Bn |
| Mar 31, 2023 | 61.60 Bn |
| Dec 31, 2022 | 38.95 Bn |
| Sep 30, 2022 | 40.24 Bn |
| Jun 30, 2022 | 37.32 Bn |
| Mar 31, 2022 | 37.74 Bn |
| Dec 31, 2021 | 33.39 Bn |
| Sep 30, 2021 | 41.89 Bn |